Date: Wednesday, March 27, 2024
Time: 10:00 am – 11:00 am PT / 1:00 pm – 2:00 pm ET
Speaker: Jessica S. Thomas, MD, PhD, MPH
Sponsored by Agena Bioscience®Register Now
Characterizing the genetic profile of lung adenocarcinomas upon initial diagnosis has become a critical step in guiding the management and treatment of patients. The need for the detection of multiple biomarkers in a single, limited diagnostic sample has driven the adoption of two complementary technologies at Houston Methodist Hospital.
In this webinar, Jessica Thomas, assistant professor of clinical pathology and genomic medicine, will share how Methodist delivers significantly accelerated results and a higher success rate for low cellularity samples by supplementing NGS with the MassARRAY platform. She will discuss how this testing paradigm has impacted patients and key considerations for implementation.
Jessica S. Thomas, MD, PhD, MPH
Associate Medical Director, Molecular Pathology Diagnostic Laboratory, Houston Methodist Hospital
Jessica Thomas obtained a Master of Public Health degree in health education from the University of Southern Mississippi in 2001, her doctorate from the Department of Microbiology, Immunology, and Parasitology in 2009, and her medical degree in 2011. She completed a combined clinical and anatomic pathology residency and a clinical fellowship in molecular genetic pathology at Vanderbilt University Medical Center’s Department of Pathology, Microbiology, and Immunology. Thomas leads the Department of Pathology and Genomic Medicine at Houston Methodist Hospital as an associate director of the Molecular Pathology Diagnostic Laboratory where she oversees a lab that serves seven hospitals in the surrounding network in the metro Houston area.
Thomas is an assistant professor of clinical pathology and laboratory medicine at Weill Cornell Medical College and Houston Methodist Academic Institute in Texas. Thomas is an active member of several professional societies, including the Association for Molecular Pathology, and is a fellow of the American Society for Clinical Pathology and the College of American Pathologists.
Darryl Irwin, PhD
Vice President, Scientific Affairs, Agena Bioscience
Darryl Irwin has been employed by Agena Bioscience (and its predecessor Sequenom) for 17 years where he has held the positions of field applications scientist and manager, custom assay development leader, and, currently, vice president of scientific affairs. Previously, Irwin led the genotyping division at the Australian Genome Research Facility. Irwin has also held positions at the Mater Laboratory Services, a hospital-based clinical genetics laboratory, and Agen Biomedical, an immuno-diagnostics manufacturer. Irwin has a doctorate from the University of Queensland in Non-Invasive Prenatal Testing and a bachelor’s degree in biotechnology from the Queensland University of Technology. Irwin has authored more than 40 publications and numerous book chapters, and he holds several patents.